MarketWatch
  • Markets
  • App
    • iOS
    • Android
    • Desktop
  • How To
    • Hindi
  • University
  • Blog
  • Exchanges
    • MCX
      • Live MCX Price
    • NSE
  • About
    • Partnerships
    • Journey
  • Agreements
    • Privacy Policy
    • Terms of Use
Select Page

Logistics platform MatchLog raises $3mn from Blue Ashva Capital, Rainmatter Climate and Capital Moneycontrol

by abhinav | Jan 20, 2022 | Analysis

MatchLog plans to grow the multi-modal share in addition to road transport and expand its footprint to more ports in India and abroad Read More

reported by at Moneycontrol

Explained: Two new oral drugs and the treatment of Covid The Indian Express

by abhinav | Nov 20, 2021 | Analysis

While several drugs have been part of treatment protocols through the pandemic, no orally administered drug had got regulatory clearance in any country until molnupiravir. Read More

reported by Kaunain Sheriff M at The Indian Express

Explained: Two new oral drugs and the treatment of Covid The Indian Express

by abhinav | Nov 20, 2021 | Analysis

While several drugs have been part of treatment protocols through the pandemic, no orally administered drug had got regulatory clearance in any country until molnupiravir. Read More

reported by Kaunain Sheriff M at The Indian Express

Has Moody’s rated India fairly visvis peers? – Moneycontrol.com

by abhinav | Oct 7, 2021 | Analysis

Even if calendar year growth of 8.8 percent and 8.3 percent are considered, India would still be the fastest-growing economy. India?s adequacy of foreign exchange reserves should be the least of the worries for credit rating agencies. Read More

reported by at Moneycontrol

This is Why Bharat Biotech’s Covaxin Failed to be the Hero of India’s Vaccination Story Against Covid News18

by abhinav | Sep 26, 2021 | Analysis

Complex processes, scattered production units, need for more safety zones and shortage of skilled staffers are some of the top reasons that restricted Bharat Biotech?s Covaxin from becoming the poster-boy of India?s vaccination story against Covid-19. Read More

reported by Himani Chandna at News18

Biocon Biologics gets license to manufacture antibody treatment for Covid Hindustan Times

by abhinav | Jul 27, 2021 | Analysis

US-based Adagio Therapeutics has allowed the company to manufacture and commericalise the ADG20-based treatment in India, as well as in select markets. | Latest News India Read More

reported by hindustantimes.com at Hindustan Times

« Older Entries

Recent Posts

  • JPMorgan downgrades Indian IT sector but bullish on these 4 IT stocks | Mint – Mint
  • PhysicsWallah raises $100 million from Westbridge, GSV Ventures, joins unicorn club – Moneycontrol
  • Gold loan platform Rupeek lays off over 180 of its employees – Moneycontrol
  • JPMorgan Sees 60% Upside In Paytm’s Beaten-Down Stock. Here’s Why… – BQ Prime
  • Policybazaar tanks 10% as CEO Yashish Dahiya plans 3.77 mn share sale – Business Standard

Recent Comments

  • 22 live with parents on CrudeOil Feb Futures: Quant-Look 21 Jan ’19

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018

Categories

  • Analysis
  • Analysis by Rahul
  • Blog
  • Chart Strategy
  • Market-Watch Staff
  • News
  • Uncategorized
  • what-is

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
All rights reserved with Umun Tech, New Delhi